Plain-English translation of NCT06588595 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After you receive a stent in your heart artery, you take two blood thinners together to prevent clots. This study is testing whether doctors should use a personalized risk calculator called ABCD-GENE to decide when and how to switch you to a single, gentler blood thinner medication. The goal is to find the right balance—protecting your heart while reducing your bleeding risk.
Early after stent placement, doctors use strong blood thinners to prevent dangerous clots, but these come with increased bleeding risk. This study wants to see if a personalized risk score can help doctors safely reduce the medication strength at the right time for each patient.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group will have their blood thinner regimen decided using a personalized risk calculator, while the other group will follow a standard switching approach. You'll take your assigned medication(s) as directed and likely have follow-up visits to monitor your blood counts and watch for any bleeding or heart-related problems. The study lasts several months and involves regular check-ins with the research team.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Florida
Enrollment target
~90 participants
Started
November 2024
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Luis Ortega, MD, PhD
University of Florida
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.